Organisation paid for research Program year 2025 Source: CMS Open Payments

Iresearch Atlanta LLC

Neither a doctor nor a teaching hospital

Research payments

$22,156,586

1,475 payments

Through program year 2025, Iresearch Atlanta LLC is reported as receiving $22,156,586 in research payments, across 1,475 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $149,489 32
2024 Research $136,285 18
2023 Research $2,089,239 128
2022 Research $7,006,472 349
2021 Research $5,610,390 353
2020 Research $4,817,868 403
2019 Research $2,346,843 192

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $7,131,298 231 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $3,679,538 33 payments
  3. Allergan Inc. $3,408,474 451 payments
  4. Vanda Pharmaceuticals Inc. $2,091,344 15 payments
  5. Sage Therapeutics, Inc. $1,629,132 154 payments
  6. ITI, Inc. $649,573 74 payments
  7. AbbVie, Inc. $620,624 54 payments
  8. Eisai Inc. $434,443 28 payments
  9. Biohaven Pharmaceuticals, Inc. $421,326 62 payments
  10. Teva Pharmaceuticals USA, Inc. $374,745 43 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $5,559,476 143 payments
  2. Evaluation of Efficacy and Safety of Iloperidone in the Treatment of Bipolar I Disorder $2,091,344 15 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $959,901 5 payments
  4. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $872,134 26 payments
  5. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Sage-217 in the Treatment of Adult Subjects With Major Depressive Disorder $565,034 47 payments
  6. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $522,171 71 payments
  7. Protocol 331-201-00081 A Multicenter, Randomized, Double-Blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment of Manic Episodes, With Or Without Mixed Features, Associated With Bipolar I Disorder $480,238 1 payment
  8. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in Theprevention of Relapse in Patients With Schizophrenia $460,980 69 payments
  9. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $441,127 31 payments
  10. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $414,496 13 payments
What the money was spent on Research payments · program years 2019–2025
  1. Professional salary support $86,882 27 payments
  2. Other $43,913 7 payments
  3. Patient care $4,750 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record